(Total Views: 735)
Posted On: 07/06/2020 5:12:50 PM
Post# of 72445
interesting summary from wallmine.com last updated June 1, 2020
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its's lead drug compound is Brilacidin, which is in Phase III study for the treatment of oral mucositis, inflammatory bowel disease, and acute bacterial skin and skin structure infection. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. In addition, it owns other compounds for treating diseases, including autism, arthritis, asthma, MS/ALS/Parkinson's, cancer, hypertensive emergency, and bacterial and fungal infections. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Beverly, Massachusetts.
https://wallmine.com/otc/ipix/officer/1124566/leo-ehrlich
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its's lead drug compound is Brilacidin, which is in Phase III study for the treatment of oral mucositis, inflammatory bowel disease, and acute bacterial skin and skin structure infection. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. In addition, it owns other compounds for treating diseases, including autism, arthritis, asthma, MS/ALS/Parkinson's, cancer, hypertensive emergency, and bacterial and fungal infections. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Beverly, Massachusetts.
https://wallmine.com/otc/ipix/officer/1124566/leo-ehrlich
(1)
(0)
